Insmed (INSM)
(Delayed Data from NSDQ)
$62.00 USD
-2.50 (-3.88%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $62.01 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
INSM 62.00 -2.50(-3.88%)
Will INSM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INSM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INSM
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
INSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
Should You Buy Insmed (INSM) Ahead of Earnings?
Other News for INSM
Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference
Insmed price target raised by $21 at BofA, here's why
Optimistic Buy Rating for Insmed’s Brensocatib Amid Strong Market Potential and Positive KOL Insights
Catalyst Watch: Tesla deliveries, Constellation Brands earnings, and the June Jobs Report
Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025